Stock Market Reviews

STRO (Sutro Biopharma, Inc.) News

Get the latest news, insights, and market updates on STRO (Sutro Biopharma, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Sutro Biopharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
  Sutro Biopharma ( NASDAQ:STRO ) First Quarter 2025 Results Key Financial Results Revenue: US$17.4m (up 34% from 1Q...
  May 10, 2025 - $STRO
• Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
  Sutro Biopharma (STRO) delivered earnings and revenue surprises of -44.44% and 25.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
  May 8, 2025 - $STRO
• Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
  - Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively - - Three INDs for wholly-owned programs anticipated in next 3 years, beginning with potential best-in-class Tissue Factor ADC, STRO-004, planned for 2H 2025 - - IND-enabling toxicology study ongoing for one program within A
  May 8, 2025 - $STRO
• Sutro Biopharma to Participate in Upcoming Investor Conferences
  SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences. Conference Details: The Citizens Life Sciences ConferenceDate: May 7-8, 2025Location: New York, NY BofA Securities 2025 Health Care ConferenceDate: May 13-15, 2025Location: Las Vegas, NV Webcasts
  May 1, 2025 - $STRO
• Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
  - Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile -SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 in Chicago, IL. The presentations
  Apr 28, 2025 - $STRO